Antibody trials that enrol mixed and comorbid disease
Test amyloid antibodies in the mixed, comorbid people clinics actually see, instead of only in tidy trial cohorts.
Overview
Until that trial exists, labels and MRI rules should stay conservative. This idea is a proposed test, not a reason to ignore exclusions.
- Trial populations that skip mixed disease · Antibody trials largely enrolled people with biomarker-supported Alzheimer’s disease and excluded much mixed, vascular, and diverse disease.
Similar pages
not linked directly; found by shared links- TechnologyApoE testing
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyAnti-amyloid antibodies
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TermARIA
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TargetAmyloid-beta
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TrialTRAILBLAZER-ALZ 2
Shares Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- CompanyEisai
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- DiagnosisMild cognitive impairment
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- RoadmapAnti-amyloid medicines
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.